Multilevel analysis: predictors of adherence from patient and physician
| Fixed effects | Model 1 (patient) | Model 2 (physician) |
| Individual level (patient) | ||
| Treatment agreement | 4.32 (1.48 to 12.6) (0.008) | 4.29 (1.41 to 13.0) (0.010) |
| Information: adaptation | 1.44 (1.05 to 1.98) (0.023) | 1.54 (1.09 to 2.17) (0.015) |
| Information: practical aspects | 0.74 (0.53 to 1.03) (0.071) | 0.66 (0.45 to 0.96) (0.030) |
| In-hospital treatment | 2.54 (1.08 to 6.01) (0.033) | |
| Time to measure adherence | ||
| <6 months | 1 | 1 |
| ≥6 months | 3.91 (1.34 to 11.4) (0.012) | 3.85 (1.22 to 12.2) (0.022) |
| DAS-28 | 1.20 (0.80 to 1.78) (0.375) | 1.17 (0.77 to 1.78) (0.471) |
| Grouping level (physician) | ||
| Treatment | ||
| First-line csDMARDS | 1 | |
| Second-line csDMARDS | 4.72 (1.61 to 13.9) (0.005) | |
| bDMARDs/tsDMARDS | 3.50 (1.14 to 10.8) (0.029) | |
| Information: efficacy | 1.71 (1.10 to 2.64) (0.016) | |
| NSAIDs | 4.21 (1.25 to 14.2) (0.021) | |
| Constant | 0.060 | 0.001 |
| Random effects | ||
| σ2 (variance) | 0.32 | 0.16 |
Cells include ORs with 95% CIs and p values unless otherwise noted.
bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.